Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: An open question

被引:69
作者
Loria, P. [1 ]
Lonardo, A. [1 ]
Bellentani, S. [4 ]
Day, C. P. [3 ]
Marchesini, G. [2 ]
Carulli, N. [1 ]
机构
[1] Univ Modena, Dipartimento Integrato Med Endocrinol Metabol & G, Div Med Indirizzo Metabol Nutr, I-41100 Modena, Italy
[2] Univ Bologna, Unit Metab Dis, Bologna, Italy
[3] Univ Newcastle, Sch Clin Med Sci, Newcastle Upon Tyne, Tyne & Wear, England
[4] Ctr Liver, Trieste, Italy
关键词
fatty liver; non-alcoholic steatohepatitis; atherosclerosis; cardiovascular risk;
D O I
10.1016/j.numecd.2007.01.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: To review available data concerning the basic science and epidemiological-clinical evidence for an association of NAFLD and cardiovascular disease. Data synthesis: Non-alcoholic fatty liver disease (NAFLD) defines alcohol-like hepatic histological lesions seen in the non-alcoholic, insulin resistant patient representing the hepatic counterpart of the metabolic syndrome. Along with insulin resistance, additional genetic, endocrine and vascular changes together with environmental stimuli-which are also involved in the pathogenesis of atherosclerosis-play a prominent role in the development and progression of NAFLD. Clinical and epidemiological studies seem to indicate that NAFLD is associated with an increased risk for cardiovascular disease but further studies are needed to confirm the available data. The mainstay of NAFLD treatment is based on the correction of the same metabolic changes that predispose to atherosclerosis. Conclusions: Non-invasive evaluation of risk for cardiovascular events is recommended in all individuals presenting with NAFLD and conversely, the presence of NAFLD should always be looked for in subjects with features belonging to the metabolic syndrome. Further studies are needed on the mechanisms linking fatty liver and vascular diseases. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:684 / 698
页数:15
相关论文
共 132 条
[1]   The natural history of nonalcoholic fatty liver disease: A population-based cohort study [J].
Adams, LA ;
Lymp, JF ;
St Sauver, J ;
Sanderson, SO ;
Lindor, KD ;
Feldstein, A ;
Angulo, P .
GASTROENTEROLOGY, 2005, 129 (01) :113-121
[2]   The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies [J].
Adams, LA ;
Sanderson, S ;
Lindor, KD ;
Angulo, P .
JOURNAL OF HEPATOLOGY, 2005, 42 (01) :132-138
[3]   Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction [J].
Adams, LA ;
Feldstein, A ;
Lindor, KD ;
Angulo, P .
HEPATOLOGY, 2004, 39 (04) :909-914
[4]   AN UPDATED CORONARY RISK PROFILE - A STATEMENT FOR HEALTH-PROFESSIONALS [J].
ANDERSON, KM ;
WILSON, PWF ;
ODELL, PM ;
KANNEL, WB .
CIRCULATION, 1991, 83 (01) :356-362
[5]   Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis [J].
Angulo, P ;
Keach, JC ;
Batts, KP ;
Lindor, KD .
HEPATOLOGY, 1999, 30 (06) :1356-1362
[6]  
Araújo LMB, 1998, DIABETES METAB, V24, P458
[7]   Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) study [J].
Assmann, G ;
Cullen, P ;
Schulte, H .
CIRCULATION, 2002, 105 (03) :310-315
[8]  
AYGUN C, 1980, EUR J GASTROEN HEPAT, V18, P175
[9]   Uncoupling protein-2 and non-alcoholic fatty liver disease [J].
Baffy, G .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2005, 10 :2082-2096
[10]   A polymorphism* in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E [J].
Baldini, M ;
Lohman, IC ;
Halonen, M ;
Erickson, RP ;
Holt, PG ;
Martinez, FD .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1999, 20 (05) :976-983